Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Jul 5;27(Suppl 2):25–35. doi: 10.1002/clc.4960271405

Secondary stroke prevention: Review of clinical trials

Mitchell S V Elkind 1,✉
PMCID: PMC6654407  PMID: 15188933

Abstract

Patients who experience a stroke or transient is‐chemic attack (TIA) are at high risk for subsequent vascular events, most commonly stroke. This article focuses on clinical trials examining secondary prevention of stroke and reviews the various commonly used methods of stroke prevention: surgical approaches, antihypertensive treatment, lipid‐ and cholesterol‐lowering medications, anticoagulant therapies, and antiplatelet therapies.

Keywords: transient ischemic attack, stroke, stroke prevention, antiplatelet

Full Text

The Full Text of this article is available as a PDF (66.0 KB).

References

  • 1. Sacco RL, Wolf PA, Kannel WB, McNamara PL: Survival and recurrence following stroke: The Framingham Study. Stroke 1982; 13: 290–295 [DOI] [PubMed] [Google Scholar]
  • 2. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR: Determinants of early recurrence of cerebral infarction: Stroke Data Bank. Stroke 1989; 20: 983–989 [DOI] [PubMed] [Google Scholar]
  • 3. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO: Survival and recurrence after first cerebral infarction: A population‐based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50: 208–216 [DOI] [PubMed] [Google Scholar]
  • 4. Sacco RL, Shi T, Zamanillo MC, Kargman DE: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology 1994; 44: 626–634 [DOI] [PubMed] [Google Scholar]
  • 5. Johnston SC, Gress DR, Browner WS, Sidney S: Short‐term prognosis after emergency department treatment of TIA. J Am Med Assoc 2000; 284: 2901–2906 [DOI] [PubMed] [Google Scholar]
  • 6. Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, Saver JL: Diffusion MRI in patients with transient is‐chemic attacks. Stroke 1999; 30: 1174–1180 [DOI] [PubMed] [Google Scholar]
  • 7. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman DG: Transient ischemic attack—proposal for a new definition. N Engl J Med 2002; 347: 1713–1716 [DOI] [PubMed] [Google Scholar]
  • 8. Clagett GP, Youkey JR, Brigham RA, Orecchia PM, Salander JM, Collins GJ Jr, Rich NM: Asymptomatic cervical bruit and abnormal ocular plethysmography: A prospective study comparing two approaches to management. Surgery 1984; 96: 823–830 [PubMed] [Google Scholar]
  • 9. The CASANOVA Study Group : Carotid surgery versus medical therapy in asymptomatic carotid stenosis. Stroke 1991; 22: 1229–1235 [DOI] [PubMed] [Google Scholar]
  • 10. Mayo Asymptomatic Carotid Endarterectomy Study Group : Results of a randomized controlled trial for asymptomatic carotid stenosis. Mayo Clin Proc 1992; 67: 513–518 [DOI] [PubMed] [Google Scholar]
  • 11. Hobson RW II, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, Wright CB: Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. N Engl J Med 1993; 328: 221–227 [DOI] [PubMed] [Google Scholar]
  • 12. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study : Endarterectomy for asymptomatic carotid artery stenosis. J Am Med Assoc 1995; 273: 1421–1428 [PubMed] [Google Scholar]
  • 13. North American Symptomatic Carotid Endarterectomy Trial Collaborators : Beneficial effect of carotid endarterectomy in symptomatic patients with high‐grade stenosis. N Engl J Med 1991; 325: 445–453 [DOI] [PubMed] [Google Scholar]
  • 14. European Carotid Surgery Trialists' Collaborative Group : MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70‐99%) or with mild (0‐29%) stenosis. Lancet 1991; 337: 1235–1243 [PubMed] [Google Scholar]
  • 15. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, Colling C, Eskridge J, Deykin D, Winn HR, for the Veterans Affairs Cooperative Studies Program 309 Trialist Group : Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. J Am Med Assoc 1991; 266: 3289–3294 [PubMed] [Google Scholar]
  • 16. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, for the North American Symptomatic Carotid Endarterectomy Trial Collaborators : Benefit of carotid endarterec‐tomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998; 339: 1415–1425 [DOI] [PubMed] [Google Scholar]
  • 17. CAVATAS Investigators : Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): A randomized trial. Lancet 2001; 357: 1729–1737 [PubMed] [Google Scholar]
  • 18. Holmes DR Jr: Best of AHA Scientific Sessions 2002. Rev Cardio‐vasc Med 2003; 4: 25–46 [Google Scholar]
  • 19. Hobson RW II: Update on the Carotid Revascularization End‐arterectomy Versus Stent Trial (CREST) Protocol. J Am Coll Surg 2002; 194: S9–S14 [DOI] [PubMed] [Google Scholar]
  • 20. Grubb RL, Derdeyn C, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Spitznagel EL, Powers WJ: Importance of hemody‐namic factors in the prognosis of symptomatic carotid occlusion. J Am Med Assoc 1998; 280: 1055–1060 [DOI] [PubMed] [Google Scholar]
  • 21. Markus H, Cullinane M: Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. Brain 2001; 124: 457–467 [DOI] [PubMed] [Google Scholar]
  • 22. Silvestrini M, Vernieri F, Pasqualetti P, Matteis M, Passarelli F, Troisi E, Caltagirone C: Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis. J Am Med Assoc 2000; 283: 2122–2127 [DOI] [PubMed] [Google Scholar]
  • 23. Gibbs JM, Wise RJS, Thomas DJ, Mansfield AO, Ross Russell RW: Cerebral haemodynamic changes after extracranial‐intracra‐nial bypass surgery. JNNP 1987; 50: 140–150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. EC/IC Bypass Study Group : Failure of extracranial‐intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985; 313: 1191–1200 [DOI] [PubMed] [Google Scholar]
  • 25. Hypertension Detection and Follow‐up Program Cooperative Group : Five‐year findings of the Hypertension Detection and Follow‐up Program. III. Reduction in stroke incidence among persons with high blood pressure. J Am Med Assoc 1982; 247: 633–638 [PubMed] [Google Scholar]
  • 26. Medical Research Council Working Party : MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985; 291: 97–104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. SHEP Cooperative Research Group : Prevention of stroke by anti‐hypertensive drug treatment in older persons with isolated systolic hypertension. J Am Med Assoc 1991; 265: 3255–3264 [PubMed] [Google Scholar]
  • 28. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P‐O: Morbidity and mortality in the Swedish Trial in Old patients with Hypertension (STOP‐Hypertension). Lancet 1991; 338: 1281–1285 [DOI] [PubMed] [Google Scholar]
  • 29. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774 [DOI] [PubMed] [Google Scholar]
  • 30. PROGRESS Collaborative Group : Randomised trial of perindopril‐based blood‐pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041 [DOI] [PubMed] [Google Scholar]
  • 31. The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin‐converting enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000; 342: 145–153 [DOI] [PubMed] [Google Scholar]
  • 32. ONTARGET/TRANSCEND Web site. Available at: www.ontar‐get‐micardis.com/default.asp. Accessed: May 2003.
  • 33. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB: Cholesterol reduction and the risk for stroke in men. A meta‐analysis of randomized, controlled trials. Ann Intern Med 1993; 119: 136–145 [DOI] [PubMed] [Google Scholar]
  • 34. Scandinavian Simvastatin Survival Study Group : Randomized trial of cholesterol‐lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
  • 35. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
  • 36. The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
  • 37. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
  • 38. Heart Protection Study Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: A randomised placebo‐controlled trial. Lancet 2002; 360: 7–22 12114036 [Google Scholar]
  • 39. Callahan A: Cerebrovascular disease and statins: A potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol 2001; 88 (7B): 33J–37J [DOI] [PubMed] [Google Scholar]
  • 40. Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457 [PubMed] [Google Scholar]
  • 41. Laupacis A, Albers G, Dalen JE, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S‐589S [DOI] [PubMed] [Google Scholar]
  • 42. Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators : The effect of low‐dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–1511 [DOI] [PubMed] [Google Scholar]
  • 43. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators : Stroke prevention in atrial fibrillation study, final results. Circulation 1991; 84: 527–539 [DOI] [PubMed] [Google Scholar]
  • 44. Petersen P, Boysen G, Gotfredsen J, Andersen ED, Andersen B: Placebo‐controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989; 1: 175–179 [DOI] [PubMed] [Google Scholar]
  • 45. EAFT (European Atrial Fibrillation Trial) Study Group : Secondary prevention in nonrheumatic atrial fibrillation after transient is‐chaemic attack or minor stroke. Lancet 1993; 342: 1255–1262 [PubMed] [Google Scholar]
  • 46. Stroke Prevention in Atrial Fibrillation Investigators : Adjusted‐dose warfarin versus low‐intensity, fixed‐dose warfarin plus aspirin for high‐risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–638 [PubMed] [Google Scholar]
  • 47. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly‐Hayes M, Sacco RL, Whisnant JP: Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999; 30: 1991–1994 [DOI] [PubMed] [Google Scholar]
  • 48. Albers GW, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114: 683S–698S [DOI] [PubMed] [Google Scholar]
  • 49. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P, for the Warfarin‐Aspirin Recurrent Stroke Study Group : A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–1451 [DOI] [PubMed] [Google Scholar]
  • 50. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP: Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625–2631 [DOI] [PubMed] [Google Scholar]
  • 51. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, and the HOPE Investigators : Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: Double blind randomised trial. Br Med J 2002; 324: 699–702 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. The Canadian Cooperative Study Group : A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53–59 [DOI] [PubMed] [Google Scholar]
  • 53. The SALT Collaborative Group : Swedish Aspirin Low‐dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cere‐brovascular ischemic events. Lancet 1991; 338: 1345–1349 [PubMed] [Google Scholar]
  • 54. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13 [DOI] [PubMed] [Google Scholar]
  • 55. The Dutch TIA Trial Study Group : A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient is‐chemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–1266 [DOI] [PubMed] [Google Scholar]
  • 56. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK‐TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiat 1991; 54: 1044–1054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–1220 [DOI] [PubMed] [Google Scholar]
  • 58. Hass WK, Easton JD, Adams HP Jr, Pryse‐Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high‐risk patients. N Engl J Med 1989; 321: 501–507 [DOI] [PubMed] [Google Scholar]
  • 59. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S: African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. J Am Med Assoc 2003; 289: 2947–2957 [DOI] [PubMed] [Google Scholar]
  • 60. CAPRIE Steering Committee : A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339 [DOI] [PubMed] [Google Scholar]
  • 61. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai H‐M: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773–1777 [DOI] [PubMed] [Google Scholar]
  • 62. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE, Bates ER: Atorvastatin reduced the ability of clopidogrel to inhibit platelet aggregation. A new drug‐drug interaction. Circulation 2003; 107: 32–37 [DOI] [PubMed] [Google Scholar]
  • 63. Serebruany VL, Steinhubl SR, Hennekens CH: Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation 2003; 107: 1568–1569 [DOI] [PubMed] [Google Scholar]
  • 64. Nakamura T, Uchiyama S, Yamazaki M, Iwata M: Effects of dipyr‐idamole and aspirin on shear‐induced platelet aggregation in whole blood and platelet‐rich plasma. Cerebrovasc Dis 2002; 14: 234–238 [DOI] [PubMed] [Google Scholar]
  • 65. Aggrenox® package insert. Ridgefield, Conn : Boehringer Ingel‐heim; March 2001.
  • 66. Chew DP, Bhatt DL, Sapp S, Topol EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta‐analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201–206 [DOI] [PubMed] [Google Scholar]
  • 67. Nappi J, Talbert R: Dual antiplatelet therapy for prevention of recurrent ischemic events. Am J Health Syst Pharm 2002; 59: 1723–1735 [DOI] [PubMed] [Google Scholar]
  • 68. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494–502 [DOI] [PubMed] [Google Scholar]
  • 69. Albers GW, Amarenco P: Combination therapy with clopidogrel and aspirin: Can the CURE results be extrapolated to cerebrovascu‐lar patients? Stroke 2001; 32: 2948–2949 [DOI] [PubMed] [Google Scholar]
  • 70. Antithrombotic Trialists' Collaboration : Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71–86 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. De Schryver EL: Design of ESPRIT: An international randomized trial for secondary prevention after non‐disabling cerebral is‐chaemia of arterial origin. Cerebrovasc Dis 2000; 10: 147–150 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES